Risk of Major Adverse Cardiovascular Events with Tofacitinib Versus Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis with or Without a History of Atherosclerotic Cardiovascular Disease: a Post Hoc Analysis from ORAL Surveillance
ANNALS OF THE RHEUMATIC DISEASES（2023）
Key words
Cardiovascular Risk
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined